TABLE 3.

Cross-resistance among approved and investigational triazoles

Species	Antifungal agent	Fluconazole/itraconazole susceptibility categorya	nb	Cumulative % inhibited at MIC (μg/ml) of:
				0.12	0.25	0.5	1	2	4	8
C. albicans	Voriconazole	RR	37	0	2.7	10.8	18.9c	37.8	40.5	40.5
		RS	38	2.6	26.3	55.3	94.7c	100
	Ravuconazole	RR	32	12.5	18.8	25.0	40.6c	43.8	46.9	46.9
		RS	38	50.0	89.5	97.4	100c
C. glabrata	Voriconazole	RR	70	0	0	0	11.4	55.7	78.6	97.1
		RS	1	0	0	100
	Ravuconazole	RR	64	0	0	0	9.4	42.2	71.9	92.2
		RS	1	0	0	0	100
C. krusei	Voriconazole	RR	39	0	15.4	79.5	100d
		RS	19	0	26.3	89.5	94.7d	94.7	100
	Ravuconazole	RR	35	0	17.1	88.6	100d
		RS	18	0	33.3	88.9	94.4d	94.4	100

^aR/R, fluconazole MIC of ≥64 μg/ml and itraconazole MIC of ≥1 μg/ml; RS, fluconazole MIC of ≥64 μg/ml and itraconazole MIC of ≤0.12 μg/ml.

^bn, number of isolates tested in each category.

^cP < 0.001 for difference in percent inhibited in RR versus RS.

^dP > 0.05 for difference in percent inhibited in RR versus RS.